Menu

Soft Tissue Detected in Millennia-Old Dino Bones

Researchers report finding evidence of red blood cells and proteins in 75-million-year-old dinosaur fossils.

Jun 10, 2015
Bob Grant

Scanning electron micrograph of samples extracted from ribs of an indeterminate dinosaur displaying mineralized collagen fibresIMAGE: SERGIO BERTAZZOScientists in the U.K. have recorded images suggesting the preservation of soft tissues, including red blood cells and collagen fibers, in fossilized dinosaur bones that date back 75 million years. Publishing their findings in Nature Communications today (June 9), a team led by researchers at Imperial College London, suggested that such well-preserved specimens of soft tissues may be more common than previously thought, even in millennia-old fossils. “We have several indications that the structures we found are consistent with red blood cells and collagen,” study coauthor Sergio Bertazzo of Imperial College told The Verge. “We were not expecting to find what we found at all. So for us, every single discovery was quite exciting.”

The researchers did not find evidence of intact genetic material, however, and the chance of recovering DNA from such old specimens is unlikely. “There is no genetic material, no evidence at all,” Susannah Maidment of Imperial College and a coauthor of the work, told The Independent. “But it would be unwise to say ‘never’ in science. Who knows what we might find if we look hard enough.”

The team scanned eight dinosaur bones from the Cretaceous period—from 145 million to 66 million years ago—that were unearthed in Canada and housed at the Natural History Museum in London for more than a century. The team used nano-analytical techniques, such as time-of-flight secondary ion mass spectrometry (ToF-SIMS), to identify amino acid fragments characteristic of collagen fibrils, plus other techniques to image what appeared to be blood cells in the claw of a therapod dinosaur.

Even though the fossils did not yield intact DNA, finding decently preserved soft tissues may open the door to myriad insights into dinosaur biology. “In ten to fifteen years we might know a lot more about dinosaurs than we ever thought possible: information about physiology and what they looked like that we could never get from the bones alone,”  Maidment told Discover’s D-brief. “Our discovery has simply shown the potential for what might be preserved if we look in the right place.”

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.